Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CS27186
- Development stage
- Unknown
- Lead developer
- Chipscreen NewWay Biosciences
- Modality
- Small Molecules
01
Overview
CS27186 is a small molecule dual inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Fibroblast Growth Factor Receptor (FGFR), currently under development by Chipscreen NewWay, a subsidiary of Chipscreen Biosciences. By simultaneously targeting the VEGFR and FGFR signaling pathways, the compound is designed to inhibit tumor-associated angiogenesis and suppress tumor cell proliferation and survival. This dual-targeting approach may provide enhanced efficacy and help overcome resistance compared to selective inhibitors of either pathway alone. CS27186 is currently in Phase 1 clinical development for the treatment of various solid tumors.
02
Targets
FGFR (FGFR family)VEGFR (VEGFR family)
Beyond the preview
Go deeper on CS27186.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CS27186.